Journal of Basic and Clinical Physiology and Pharmacology最新文献

Objectives: To assess the belching-related esophageal events in healthy volunteers during and after fast-food meals.

Methods: Ten adult healthy volunteers had two lunches with a Big Mac^® on different days, accompanied or not by Coca-Cola (500 mL, pH<3) in a random way. We assessed prandial and 2 h postprandial esophageal events using impedance-pH monitoring.

Results: During meals with Coca-Cola, most signed belching (68 %) were concomitant with prolonged esophageal acidification or acid reflux, and the belching number was superior [median: 9.5 (IQR 4.7-14) vs. 0 (0-3); p=0.002] and less frequently represented by pure gas (24 % vs. 92 %; p<0.001) than in meals without Coca-Cola. Postprandial belching did not differ either in frequency [median: 15.5 (6-20.2) vs. 13.5 (10.7-20.5); p=0.739] or in type [(median %) pure gas: 6.7 % vs. 11.7 %; during acid reflux: 64.6 % vs. 51.7 %; during nonacid reflux: 22.5 % vs. 22.2 %; p=0.300), with more than 80 % of belching coincident with asymptomatic liquid reflux, regardless of Coca-Cola intake. Postprandial gastroesophageal reflux and esophageal acid exposure were similar, irrespective of Coca-Cola intake.

Conclusions: In healthy volunteers, a fast-food meal with Coca-Cola provoked a prompt reaction with increased prandial belching and esophageal acidification. Coca-Cola did not change postprandial belching, often accompanied by silent gastroesophageal liquid reflux.

Objectives: The effectiveness of diabetes management depends significantly on patients' knowledge of key concepts such as carbohydrate counting, bolus timing, duration of insulin action, and the interpretation of trend arrows. This study aims to evaluate the understanding of these concepts among patients with type 1 diabetes who are using advanced technologies.

Methods: From January 2024 to July 2024, consecutive patients with type 1 diabetes who met inclusion criteria were enrolled. Participants were asked to complete a questionnaire to assess their retention of key concepts for T1D management. Each patient completed the questionnaire independently in a private room before their medical appointment.

Results: This study evaluated therapeutic education in adult T1D patients in Campania, Italy, who use advanced diabetes technologies. Despite most patients having long-term diabetes, significant knowledge gaps were found in diabetes management. Only 40 % of CGM users correctly correlated sensor data with capillary glucose, and 19 % erroneously believed they were identical. Just 25 % patients knew their insulin-to-carbohydrate ratio, and only 56 % accurately calculated carbohydrates. Even among users of advanced hybrid closed-loop systems, similar deficiencies existed.

Conclusions: Understanding of key concepts necessary for effective management of diabetes using advanced technologies remains insufficient in a cohort of Italian patients.

Objectives: This study will identify strengths and weaknesses of ADR reporting forms of study countries.

Methods: This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries. We similarly collected and analysed ADR forms from Australia, Canada, India, South Africa, the UK, and the US. Data fields were grouped into different subgroups.

Results: An analysis of ADR reporting forms from six countries revealed a total of 70 data fields. The US-FDA's FORM 3500 has the most fields at 50 (71 %), followed by India's CDSCO with 42 fields (60 %). According to WHO-UMC recommendations, Canada and Australia have the highest number of suggested fields at 10 (83 %). All forms were one page long except for the US-FDA's, which is five pages.

Conclusions: Improving patient feedback and organisational engagement is essential to raise awareness of the reporting system. A proposed generic ADR form provides detailed information for causality assessment and could serve as a basis for a standard global reporting form.

The application of natural occurring compounds in the treatment of human diseases has been increased in the recent decades due to the biocompatibility and pleiotropic impacts of these agents along with significant health-promoting effects. Among them, resveratrol has been shown to be of importance, since it can exert various biological and pharmacological activities. Moreover, resveratrol generally demonstrates good biosafety and biocompatibility that can further improve its application in clinical studies. In terms of biological activities, the antioxidant and anti-inflammatory activities of resveratrol has been of importance and they are useful in the prevention of diabetes and neurological diseases. The antioxidant activity of resveratrol can result from its function in enhancing levels of antioxidant factors such as catalase and superoxide dismutase, and reduction in ROS levels. Moreover, resveratrol can reduce inflammation and downregulate related pathways such as NF-κB. Beyond this, resveratrol has been shown to be beneficial in the treatment of human diseases such as diabetes mellitus, cancer (suppressing tumorigenesis or acting as chemopreventive agent) and alleviation of neurological diseases, among others. Such protective impacts of resveratrol would be discussed in the current review with a focus on underlying molecular factors. In addition, nanoparticles have been significantly applied in the treatment of human disease through delivery of resveratrol and since pharmacokinetic profile of resveratrol is poor, the application of delivery systems can accelerate therapeutic index of this natural product. However, clinical application of resveratrol-loaded nanoparticles in the clinical level relies on the biocomaptibility and safety of these structures along with their efficacy.

Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.

Introduction: Superficial lymph node (LN) enlargement is a common ultrasonographic finding and can be associated with a broad spectrum of conditions, from benign reactive hyperplasia to malignant lymphoproliferative disorders (LPDs). LPDs, which include various hematologic malignancies affecting lymphoid tissue, present with diverse immune-morphological and clinical features, making differentiation from other malignant causes of lymphadenopathy challenging.

Content: Radiologic assessment is crucial in characterizing lymphadenopathy, with ultrasonography serving as a noninvasive and widely available imaging modality. High-resolution ultrasound allows the evaluation of key features such as LN size, shape, border definition, echogenicity, and the presence of abnormal cortical thickening, loss of the fatty hilum, or altered vascular patterns, which aid in distinguishing benign from malignant processes.

Summary: This review aims to describe the ultrasonographic characteristics of lymphadenopathy, offering essential diagnostic insights to differentiate malignant disorders, particularly LPDs. We will discuss standard ultrasound techniques, including grayscale imaging and Doppler ultrasound, and explore more advanced methods such as contrast-enhanced ultrasound (CEUS), elastography, and artificial intelligence-assisted imaging, which are gaining prominence in LN evaluation.

Outlook: By highlighting these imaging modalities, we aim to enhance the diagnostic accuracy of ultrasonography in lymphadenopathy assessment and improve early detection of LPDs and other malignant conditions.

Objectives: In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower doses (SC dose of 0.25 mg; PO dose of 3 mg) was examined by utilizing a sensitive bioanalytical method.

Methods: Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h. The samples were assayed for semaglutide with an analytical range of 0.05-50 ng/mL. The pharmacokinetic parameters were estimated using a non-compartmental approach and were used to evaluate the comparative bioavailability of semaglutide.

Results: The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses. The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered. Overall, the study drug was well tolerated, and no serious adverse events were reported.

Conclusions: The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method. This method will enable more investigations into the pharmacokinetics of all formulations of semaglutide at lower doses, which will enable a better understanding of its' disposition in healthy subjects and in patients.

Objectives: This manuscript reviews advancements in oral and maxillofacial surgery, encompassing minimally invasive techniques, innovations in implant dentistry, regenerative medicine, innovations in temporomandibular joint, and novel methodologies in salivary gland surgery.

Methods: A comprehensive analysis of recent developments in the field is presented, focusing on the integration of new technologies and biological therapies. Emphasis is placed on minimally invasive procedures, virtual surgical planning with CAD/CAM and 3D printing, implant design and placement innovations, and regenerative approaches.

Results: Minimally invasive procedures, often employing endoscopic or robotic assistance, reduce surgical morbidity and accelerate patient recovery. Virtual surgical planning and 3D printing enhance pre-surgical accuracy. Innovations in implant design, surface modification, and guided surgery improve prosthetic outcomes. Regenerative medicine and tissue engineering, including the use of growth factors and stem cells, offer new options for tissue restoration. In temporomandibular joint disorders, these strategies aim to improve function and reduce reliance on arthroplasty. The use of superficial dermal substitutes in salivary gland surgery reduces complications such as Frey syndrome.

Conclusions: These advancements reflect a paradigm shift in oral and maxillofacial surgery, enhancing patient care and expanding the field's potential through precision, biologically based therapies, and less invasive approaches.

Objectives: The Sarno river basin (Italy) is a region characterized by significant environmental pollution, raising concerns about heavy metal exposure in residents. The PREVES-STOP Initiative aims to address these concerns. This study investigates the prevalence of detectable blood lead (Pb) and cadmium (Cd) in a cohort of adults from this area and examines associations with key health indicators.

Methods: This study analyzed data from 75 adults (aged 30-65) participating in the PREVES-STOP Initiative. Participants completed comprehensive questionnaires assessing demographics, medical history, lifestyle factors (smoking, physical activity), and psychometric measures (fatigue, anxiety/depression, sleep quality). Blood samples were analyzed for Pb and Cd using established methods, with detectable levels defined as≥2 μg/100 mL (Pb) and ≥0.5 μg/L (Cd).

Results: Detectable Pb (18.67 % of participants) was significantly associated with higher systolic blood pressure, hemoglobin, and MCH, and inversely correlated with HDL cholesterol. Poorer sleep quality was also associated with detectable Pb. Detectable Cd (28 % of participants) was significantly associated with higher systolic blood pressure, LDL cholesterol, neutrophil count, and with higher odds of having a history of autoimmune diseases. Multivariate regression models, adjusting for age, sex, smoking status, and BMI, were used to determine these associations.

Conclusions: This study demonstrates that even low-level exposure to Pb and Cd in the Sarno river basin is associated with adverse clinical outcomes. The PREVES-STOP Initiative provides a valuable framework for community-based health assessment and intervention in areas affected by environmental pollution.